Stock Events

Stock Events

ProKidney 

$1.9200
46
+$0.01+0.52% Thursday 20:00
+$0.06+3.13%Thursday 23:30After hours

Statistics

Day High
1.92
Day Low
1.905
52W High
3.48
52W Low
1.3
Volume
36,958
Avg. Volume
-
Mkt Cap
401.14M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.16
-0.15
-0.13
-0.12
Expected EPS
-0.154104
Actual EPS
N/A

Financials

-7,725.2%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
893,000Revenue
-68.99MNet Income

Analyst Ratings

12.00Average Price Target
The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PROK. It's not an investment recommendation.
NVIDIA
10
NVDA
Rocket Lab
9
RKLB
Microsoft
7
MSFT
Alphabet
6
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is developing treatments for kidney diseases, including APOL1-mediated kidney diseases, which could compete with ProKidney's regenerative medicine approach.
Aurinia Pharmaceuticals
AUPH
Mkt Cap2.17B
Aurinia Pharmaceuticals focuses on the development of therapies for kidney diseases, including lupus nephritis, potentially competing in the kidney treatment space.
Akebia Therapeutics
AKBA
Mkt Cap243.47M
Akebia Therapeutics focuses on kidney disease treatments, including anemia caused by chronic kidney disease, making it a direct competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a broad portfolio of drugs, including those for kidney conditions, competing on a wide front in the kidney treatment market.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops therapies for genetic diseases, some of which may involve kidney function, placing it as a potential competitor in the broader market for kidney-related treatments.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diverse portfolio that includes treatments for kidney cancer and other kidney-related conditions, making it a competitor in the kidney health market.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, offers medications for chronic kidney disease and complications, competing in the kidney treatment landscape.

About

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Show more...
CEO
Bruce Culleton
Employees
231
Country
Cayman Islands
ISIN
US74291D1046

Listings

XNAS
US
PROK
BOATS
BOATS
PROK.BOATS

0 Comments

Share your thoughts

FAQ

What is ProKidney stock price today?▼
The current price of PROK is $1.92 USD — it has increased by +0.52% in the past 24 hours. Watch ProKidney stock price performance more closely on the chart.
What is ProKidney stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange ProKidney stocks are traded under the ticker PROK.
Is ProKidney stock price growing?▼
PROK stock has risen by +4.92% compared to the previous week, the month change is a +17.79% rise, over the last year ProKidney has showed a -16.52% decrease.
What is ProKidney market cap?▼
Today ProKidney has the market capitalization of 401.14M
When is the next ProKidney earnings date?▼
ProKidney is going to release the next earnings report on November 16, 2026.
What were ProKidney earnings last quarter?▼
PROK earnings for the last quarter are -0.15 USD per share, whereas the estimation was -0.14 USD resulting in a -7.14% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ProKidney revenue for the last year?▼
ProKidney revenue for the last year amounts to 893,000 USD.
What is ProKidney net income for the last year?▼
PROK net income for the last year is -68.99M USD.
How many employees does ProKidney have?▼
As of September 04, 2026, the company has 231 employees.
In which sector is ProKidney located?▼
ProKidney operates in the Health & Wellness sector.
When did ProKidney complete a stock split?▼
ProKidney has not had any recent stock splits.
Where is ProKidney headquartered?▼
ProKidney is headquartered in WINSTON-SALEM, Cayman Islands.